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CObjectives: Many regulatory agencies require that manufacturers es-
tablish both efficacy and cost-effectiveness. The statistical analysis of
the randomized, controlled trial (RCT) outcomes should be the same for
both purposes. The question addressed by this article is the following:
for survival outcomes, what is the relationship between the statistical
analyses used to support inference and the statistical model used to
support decision making based on cost-effectiveness analysis (CEA)?
Methods: We performed a review of CEAs alongside trials and CEAs
based on a synthesis of RCT results, which were submitted to the Na-
tional Institute for Health and Clinical Excellence (NICE) Technology
Appraisal program and included survival outcomes. We recorded the
summary statistics and the statistical models used in both efficacy and
cost-effectiveness analyses as well as procedures for model diagnosis
and selection. Results: In no case was the statistical model for efficacy
and CEA the same. For efficacy, relative risks or Cox regression was
used. For CEA, the common practice was to fit a parametric model to O
comp
Com
.
al So
oi:10.1016/j.jval.2011.01.008he control arm, then to apply the hazard ratio from the efficacy anal-
sis to predict the treatment arm. The proportional hazards assump-
ion was seldom checked; the choice of model was seldom based on
ormal criteria, and uncertainty inmodel choicewas seldom addressed
nd never propagated through the model. Conclusions: Both infer-
nce and decisions based on CEAs should be based on the same statis-
ical model. This article shows that for survival outcomes, this is not
he case. In the interests of transparency, trial protocols should specify
common procedure for model choice for both purposes. Further, the
ufficient statistics and the life tables for each arm should be reported
o improve transparency and to facilitate secondary analyses of results
f RCTs.
eywords: cost-effectiveness analysis, cox proportional model, effi-
acy, exponential, hazard ratio, parametric distributions, weibull.
opyright © 2011, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Survival analysis is used to describe the analysis of data in the
form of times from awell-defined time origin until the occurrence
of some particular event or end point [1]. Survival times are fre-
quently censored. This arises if patients fail to reach the end point,
for example, death or disease progression, before the end of the
study period, or if they become lost to observation. If any observa-
tions are censored, the sample mean is a biased estimate of the
true mean, whether censored observations are included or not.
Survival analysis solves the problem of censoring by calculat-
ing, at each time point, the probability that a patient reaches the
end point, given that he or she has survived that far. If patients are
censored, they are simply dropped from the at-risk denominator.
The analysis is based on the hazard at each time point and leads to
the nonparametric Kaplan-Meier curves illustrated in Figure 1.
ote that in this figure, no patient is followed beyond 32 months; at
his point, an estimated 29% of patients for the treatment arm and
3% for the control arm have still not reached the end point. To es-
ablish the clinical effectiveness of a new treatment, the semipara-
etric Cox regression is usually used. This method allows, if the
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Committees, but was not involved in the appraisal of sorafenib.
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098-3015/$36.00 – see front matter Copyright © 2011, Internation
ublished by Elsevier Inc.proportional hazards assumption holds, estimation of a treatment
effect in the form of a hazard ratio without assuming any particular
form of probability distribution for the hazard function.
To establish the cost-effectiveness of a new treatment, the
health benefits are most frequently measured by using quality
adjusted life-years (QALYs) [2]. QALYs are calculated by summing
the time spent in a health state weighted by the utility value as-
sociated with the health state, thus incorporating both health-
state utility and length of survival. Therefore, although the statis-
tician can generate a relative effect measure in the form of a
hazard ratio to compare two samples, the economistmust adopt a
strategy that permits the estimation of the expected time in each
health state, despite censored data. Usually a parametric ap-
proach is takenwhere a specific distributional form is assumed for
the time-to-end point data. A wide range of such distributions can
be fitted to the data. Once a distributional form has been chosen,
extrapolation of the survival curve can be undertaken, as illus-
trated in Figure 1, and mean survival—effectively the area under
the curve—can be estimated.
There is, then, a possibility that twodistinct statistical analyses
may be carried out on the same data set: one for the purposes of
eting interests. A.E. Ades is a member of the NICE Appraisals
munity Medicine, University of Bristol, Canynge Hall, 39 Whatley
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
641V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 6 4 0 – 6 4 6inference about treatment efficacy and the other for the purpose
of cost-effectiveness analysis (CEA). The purpose of this article is
therefore to review recent literature to see how investigators have
approached this problem and whether they were aware of the
potential contradictions that could arise. We reviewed two kinds
of literature—CEAs alongside randomized, controlled trials (RCTs)
and CEAs with evidence synthesis—to see how investigators ex-
press relative treatment effects in clinical effectiveness reports
and how—and indeed whether—their efficacy analysis informs
the estimates of mean time in states or whether efficacy and CEAs
are based on different statistical models. We also assessed the
extent to which key assumptions (proportional hazards, paramet-
ric form) are checked and whether the uncertainties in these as-
sumptions are appropriately propagated through the decision
model.
In the Discussion section, we consider the impact of a mis-
match between efficacy and CEAs on the transparency and integ-
rity of decisionmaking based on CEAs and onmethods for synthe-
sis of survival time data. We also examine possible remedies.
Methods
Sampling frame
To provide a manageable sampling frame, we use the most recent
CEAs commissioned and issued by the National Institute for
Health and Clinical Excellence (NICE) Technology Appraisal pro-
gram including survival outcome(s), working backward from June
2008 to September 2004. The assessment reports provided by the
NICE during this period were reviewed and were included in this
review if they contained at least one survival outcome in the anal-
ysis. This 4-year period should generate a representative view of
current practice. The review included 13 CEAs alongside RCTs or
systematic review but no meta-analysis, of which 7 were single
technology appraisals (STAs), in which the manufacturer submis-
sions are reviewed by an academic evidence review group and 6
multiple technology appraisals (MTAs), in which the main report
is prepared by an academic assessment group. We also examined
11 CEAs based on meta-analysis or indirect comparison (3 STAs
and 8 MTAs). We chose to base our study on CEAs commissioned
and issued by the NICE for several reasons. Submissions to the
NICE are relatively uniform because they adhere closely to a pre-
specified methodology [3,4] that is widely regarded as represent-
ing a high standard [5]. Furthermore, the NICE is seen as a role
model for the implementation of CEAs and is being closely
Fig. 1 – Overall survival for two treatment arms for a typical
trial selected from the look-back review. The stepped lines
are the Kaplan-Meier estimates; the smooth curves show a
proportional hazards Weibull model, from which the mean
survival time under each treatment can be estimated.watched by health care policymakers throughout Europe and theUnited States [6]. In addition, theNICEmakes the complete assess-
ment reports available in English on their Web site. For the STAs,
our analyses were based, where possible, on the initial submis-
sions. We relied on the evidence review group’s description of
manufacturer submissions. Several alternate analyses may be
presented as part of the appraisal process; these were not exam-
ined systematically, but we refer to these further in the Discussion
section. For theMTAs, our analyses were based on the assessment
groups’ reviews.
Data extracted
Each publication was scrutinized in detail. Numerous features of
the studies were extracted and recorded separately for 1) for CEAs
alongside an RCT and 2) for CEAs based on evidence synthesis. A
large number of study methods and results were recorded. We
report here on the absolute and relative effect measure for the
efficacy and CEA, the statistical models used for absolute and rel-
ative effects, and procedures adopted for checkingmodel assump-
tions, such as proportional hazards and the parametricmodel, and
methods used for model selection. We also recorded whether the
CEA was deterministic or probabilistic. For CEAs based on meta-
analysis or indirect comparison, we also recorded the number of
studies included in the synthesis and, where possible, the relative
effect and the absolute effect for efficacy in each study and in the
synthesis. Based on these two large spreadsheets, the information
extracted was tabulated as presented in the Results section. We
focused especially onwhether the statisticalmodel underlying the
CEA is the same as the statistical model underlying the efficacy
analysis. When the study included two survival outcomes with
different features, both features are shown in the summary tables.
For some studies, the information requiredwas not available in
the material examined or the explanation about the models was
imprecise and/or incomplete. We tried to reflect appropriately the
information provided, and we take responsibility for any errors
made in tabulating the results.
Results
CEAs alongside one RCT
In Table 1 ([7–19) 14 of the 16 CEAs were based on parametric
models (first 3 columns). On the other hand, none of the efficacy
analyses specified parametric models (first two lines). In no case
was the same model used for efficacy and cost-effectiveness.
In 12 of the 16 efficacy analyses, a hazard ratio measure was
generated usually based on a Cox model (although the method
was not specified in four cases). In CEAs, in two cases, separate
models were fitted to each arm (first column of Table 1). In these
two cases, the treatment effect is fundamentally different from
what was assumed in the efficacy analysis; the assumption of a
hazard ratio that is constant over time is effectively abandoned. In
four cases, a new parametric model was estimated for the control
arm, and then a prediction for the treatment arm was generated
by assuming proportional hazards and by applying to the control
arm the hazard ratio estimated by Cox regression in the efficacy
analysis (second column of Table 1).
We found that no study reported that the proportional hazards
assumption had been formally tested, and none provided any ra-
tionale or justification. No study stated that the hazard ratios was
estimated, or re-estimated, from a parametric model. Regarding
the parametric form of the survival distribution, the exponential,
Weibull, Gompertz, and log-logistic and log-normal distributions
were used and graphically assessed (Table 2). TheWeibull and the
exponential distributions are the most frequently encountered.
Six studies did not state whether different models had been com-
pared. For the five other studies, the number of parametric distri-
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642 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 6 4 0 – 6 4 6butions compared varied between two and four. Four studies re-
ported that the choice of model was based on best graphical fit
against the Kaplan-Meier curves. Only one study selected the dis-
tribution using a statistical criterion, which was the Akaike Infor-
mation Criterion. Four of the five studies using an exponential
distribution did not report having compared it with other para-
metric distributions, and the fifth one only compared the expo-
nential distribution to one other distribution. Only one study [19]
checked the sensitivity of the results to model assumptions by
using the Weibull parameter estimates, the exponential esti-
mates, and the lower and upper values around the fitted expo-
nential in sensitivity analyses. Otherwise, there was no attempt
to take into account the uncertainty about which model was
appropriate.
Results for CEAs based on evidence synthesis
In the 11 CEAs based on evidence syntheses, whether on pairwise
meta-analysis or on indirect ormixed treatment comparisons [20],
manufacturers presented either hazard ratios or risk ratios when
describing results from their own trials. The summary statistics in
the synthesis were pooled (log) hazard ratios (7) or (log) relative
risks (3) (Table 3) ([21–31). To carry out CEAs, these hazard or risk
ratios were again applied to “baseline” parametric models esti-
mated mostly from the baseline in the manufacturer’s trial. The
manufacturers tend to have access to individual patient data (IPD)
from their own trial, but not to the IPD of the other trials included
in the evidence synthesis. This obliges them to use the summary
statistics reported in the publications of the other trials, either
hazard ratios or medians.
Seven studies did not report having compared differentmodels
(Table 4). One study reported testing an exponential and aWeibull
distribution: the Weibull distribution was chosen based on the fit
against the Kaplan-Meier curves. One study explicitly states that
no comparison of different models could be possible due to the
Table 2 – CEAs alongside trial: parametric and
proportional hazards assumptions.
References Total
Parametric models in the 14
analyses (from the 11
studies): model
diagnostics and selection
Distributions tested
Exponential [7, 11, 13, 14, 18, 19] 6
Weibull [7, 8, 12, 14, 16, 19] 6
Gompertz [16] 1
Log-logistic [7, 14] 2
Log-normal [7] 1
Unspecified [8, 9, 15] 3
Choice rationale
Best graphical fit against KM
curves
[8, 14, 16, 19] 4
Akaike Information
Criterion
[7] 1
Not stated [9, 11–14, 18] 5
Was the proportional hazards
assumption tested in the
12 analyses (from the 9
studies) using this
assumption in the CEA?
Yes 0
Not stated [7–9, 11, 13, 15, 16, 18, 19] 9
References in bold indicate the distribution chosen.
CEAs, cost-effectiveness analyses.lack of IDP. The proportional hazards assumption was tested in
T M P S N D N T H
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643V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 6 4 0 – 6 4 6two of six studies. The method used is not reported for one study,
whereas for the other, a plot of ln(ln(S(t)) against ln(t) was exam-
ined. (Parallel lines for each treatment suggest proportional haz-
ards.) No attempt was made to incorporate the uncertainty in the
choice of the model directly into the CEA.
Discussion
Interpretation of findings
The statistical model underlying the estimate of treatment effi-
cacy should ideally be the same as the statisticalmodel underlying
the CEA, and yetwe found that in 24 unselected, recent technology
appraisals involving survival analysis submitted to the NICE, this
was never the case. What makes this so surprising is that there is
no technical reason why both efficacy and cost-effectiveness can-
not be served by the same statistical model and indeed by the
same relative summary measure. Instead of a single coherent
analysis, we found that a parametric model was fitted to the con-
trol arm or the standard treatment, and a hazard ratio or relative
risk estimated in a separate model was then applied to this base-
line to generate the treatment arm for the CEA. In most of the
cases, this hazard ratio was from the efficacy analysis and thus
from a Cox proportional model. This practice has many implica-
tions.
First, just from a statistical point of view, the Cox hazard ratio
will not have the same numerical value as a hazard ratio that
would be estimated by fitting the parametric model to both arms.
Yet, if we believe that the parametric model correctly represents
the standard treatment effect andwe accept proportional hazards,
then there is no reason to not use the parametric model to esti-
mate the relative treatment effect. Second, overlaying the hazard
ratio from one analysis onto a baseline arm from a different anal-
ysis will overstate the uncertainty in the analysis because the co-
variation between baseline and treatment effect that would be
expressed in a single coherent analysis is lost, resulting eventually
in an incorrect characterization of the uncertainty in incremental
net benefit. Because cost-effectiveness models based on survival
data are highly nonlinear functions of the survival parameters, the
probabilistic analyses required for decision making under param-
eter uncertainty will then be biased. Finally, as we have to assume
a distribution for the baseline treatment, we remove the advan-
tage of the Cox model; therefore, the question of keeping the pro-
portional hazards assumption should be properly tested. If the
proportional hazards assumption does not hold, then the hazard
ratio obtained from a Coxmodel ismeaningless, and applying it to
a parametric form for the baseline will give incorrect inference.
Note also that some of the parametric distributions, such as the
log-logistic distributions, cannot be parameterized as a propor-
tional hazards model.
The analyses of the studies alongside trials suggest that most
investigators were aware of the awkward position in which they
found themselves: a Cox regression analysis had been prespeci-
fied in the original protocol and yet a parametric model was
needed for cost-effectiveness. They preferred to apply the Cox
hazard ratio from the nonparametric efficacy analysis to their
parametric model, even though this was not entirely “correct,”
rather than produce a completely new parametric analysis giving
a different estimate of the hazard ratio. The “hybrid” estimates
produced in this way are not, of course, the best fit to the data,
given the model.
For CEAs based on evidence syntheses, investigators face
greater difficulties. They have fewer options because the individ-
ual patient data needed to select, test, and fit parametric models
will only be available from the trials sponsored by the manufac-
turermaking the submission. Therefore, alternative evidence syn-
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644 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 6 4 0 – 6 4 6theses to obtain expected survival times or expected times to pro-
gression are impossible to implement.
A further, less-than-satisfactory aspect of these analyses is the
inadequate checking of assumptions. The proportional hazards
assumptionwas seldom checked, and the use of formal criteria for
choice of parametricmodelswas highly infrequent. Uncertainty in
model choice was seldom addressed at all and never formally in-
corporated or propagated through the decision model. Interest-
ingly, in this look-back review, there was no use, or evenmention,
of methods capable of reflecting model uncertainty, neither the
flexible multiparameter generalized F distribution that contains
ost of the standard shapes [32] nor the newmethods for flexible
pline curves [33]. A series of recent publications on the use of
exible distributions andmodel averaging [34–36] indicate a grow-
ng interest in the problem.
Although we have focused on the assessment group submis-
ion and on the review group’s description of the initial manufac-
urer submissions, several alternative analysesmay be performed
n the course of the appraisal process, and the final decision is
haped by a wide range of other information and comments from
takeholders. A further exercise might be to track the different
nalyses through each appraisal and examine alternative analy-
es and how they influenced the decision. Manufacturer submis-
ions could be examined directly as well as peer-review publica-
ions of key trials before and after the submission. This could
mprove the accuracy of the reviewwe have conducted andwould
ertainly offer rich insights into how the analyses were motivated
ndused, but itwould be unlikely to change the conclusions of this
tudy. In cases in which de novo survival analyses were under-
aken by the evidence review group [8,11,15,26], one looked at fur-
her parametric curves, two examined the area under the KM
urve, and one used external data. It is therefore unlikely that
urther examination of our sample of studies would change our
onclusions.
Impact of the various models on medical decision making
Setting aside the incoherence of current practice from the view-
point of statistical method, the lack of protocol or guidelines ad-
dressing the CEAs, and particularly the choice of parametric mod-
el(s), leaves those responsible for choosing a model a very
substantial level of freedom and creates a danger of arbitrary
choice of model or choice of model to favor a particular product.
It was not possible in this study to document whether the use
of an alternative model that was equally compatible with the data
would have led to different conclusions on efficacy or to a different
decision on cost-effectiveness. This would only be possible with
access to the individual data and the full model used for the CEAs.
It is unlikely that relative efficacy measures such as the hazard
ratio would be materially different, and it is also likely that the
direction of the differences between treatments in expected sur-
vival or expected time to progression would be unaltered, unless
there were severe departures from proportional hazards.
It is worth remembering, however, that a substantial majority
of submissions to reimbursement agencies such as the NICE may
be on the very margin of cost-effectiveness because manufactur-
ers naturally tend to set prices as high as they can without going
over the cost per QALY-gained threshold. Under these circum-
stances, only minor changes in the model are needed to change a
“yes” decision to a “no” or vice versa. At the NICE, for example, the
issue of whether the parametric model assumed by the manufac-
turer is justified or whether different results might be obtained
with different models equally well supported by the evidence has
been raised during the appraisal process on a number of occasions
and has once been subject to an appeal [37].Possible remedies
Despite the increasing use of CEA alongside RCTs, and the use of
systematic reviews and CEAs in reimbursement decisions in sev-
eral countries, such as the NICE in England and the Scottish Med-
icines Consortium in Scotland, the design and analysis of RCTs
with survival outcomes are oriented toward ratio-basedmeasures
without regard to expected survival time. At the trial design stage,
CEA is still at present regarded as an add-on, to be conducted by
other people, after the efficacy analysis. Many of the trials are
designed to obtain licenses, and one of the contributing causes
may be the separation of regulatory and reimbursement processes
and their very different requirements for data. Possibly efforts to
link the two would encourage the development of joint analysis
protocols, although the different requirements of different agen-
cies may make this challenging.
The Cochrane Handbook for systematic reviews of interven-
tions [38] advises that the intervention effect should be expressed
s a hazard ratio. The CONSORT statement [39] notes that “for
urvival time data, the measure could be the hazard ratio or dif-
erence inmedian survival time.” These guidelines neither recom-
end reporting an estimate of themean survival nor do they spec-
fy how the survival analysis results of RCTs should be included in
conomic evaluations. As we have seen, this raises the possibility
f having different statistical models for the same data set, used
or inference on treatment efficacy and for economic decision
aking. The twomodels cannot both be correct; one of them is not
ven the best fit to the data given its own assumptions, and we
ave seen that in some cases they are fundamentally different. In
he absence of any protocol, the choice of analysis for CEA is vir-
ually arbitrary because many models might be equally compati-
le with the evidence.
One remedy would be for trial protocols to include prespecifi-
ation of a single analysis to be used in both efficacy and cost-
Table 4 – CEAs based on evidence synthesis: parametric
and proportional hazards assumptions.
References Total
Parametric assumptions in the 10
analyses (from the 8 studies):
model diagnostics and selection
Distribution tested
Exponential [24, 27, 30] 3
Piecewise exponential [26] 1
Weibull [22, 24, 25, 28, 29] 5
No further investigation because of
lack of IPD
[30] 1
Choice rationale
Best graphical fit against KM curves [24] 1
Weibull graphical plot of
ln(ln(S(t)) against ln(t)
[22, 28] 2
Not stated [25–27, 29, 30] 3
Were the proportional hazards
assumption tested in the 10
analyses (from the 8 studies)
using this assumption in the
CEA?
Yes: graphical plot of ln(-ln(S(t))
against ln(t)
[22] 1
Yes: assumption tested but
commercial/ academic in
confidence information removed
[29] 1
Not stated [24–28, 30] 6
References in bold indicate the distribution chosen.
CEAs, cost-effectiveness analyses; IPD, individual patient data; KM,
Kaplan-Meier.
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645V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 6 4 0 – 6 4 6effectiveness research. Further research will be needed before
joint protocols can be designed, and this will involve careful ex-
amination of a wide range of survival data, experiments with dif-
ferent curve fitting methods, and perhaps simulation studies to
assess the effects of model choice. A joint prespecified protocol
would not, of course, dictate a particular choice of parametric
model, or even a “menu” of standard models. Instead it would
specify a single, common process for model selection. It would
also be an opportunity to prespecify methods for analyzing mor-
tality data in trials in which patients may switch to other treat-
ments (crossover) after tumor progression [40] and may even en-
ourage trial designs that would be easier to analyze in this
espect. The need for prespecified protocol is something that could
erhaps be championed by bodies like the Cochrane Collaboration
r the International Committee on Harmonisation.
A second remedy that would immediately transform the prob-
em, although it would not solve the problem of the protocol, re-
ates to the reporting and availability of results. The CONSORT
tatement [36] requires that in trials with continuous outcomes,
the mean and SD are reported for each arm, whereas numerators
and denominators are required for trials with dichotomous out-
comes. These constitute the sufficient statistics for each arm.
CONSORT’s advocacy of the hazard ratio or difference in median
survival time for survival data is surprising for three reasons: first,
these are not sufficient statistics; second, they specify a measure
of the relative effect rather than an effect for each arm (generally
required for CEA); and third, the hazard ratio requires a propor-
tional hazards assumption and is therefore stronglymodel depen-
dent. A more consistent approach would require the sufficient
statistics for each arm. These are the life tables: the numbers of
events and numbers of patients at risk each time that there is an
event. Although the provision of the life table for each arm would
not allow covariate analysis and adjustment, they would other-
wise contain the same information as the IPD. The provision of the
life-table data would allow analysts to test assumptions and to
evaluate different models and therefore would improve the trans-
parency in economic evaluations and would greatly facilitate evi-
dence synthesis.
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